Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Launched by SAMSUNG MEDICAL CENTER · Jun 9, 2016
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well the small blood vessels in the heart are functioning in patients with cardiac amyloidosis, a condition where abnormal proteins build up in the heart tissue. Researchers will measure how well blood flows through these vessels and check for any signs of microvascular disease, which is when these tiny blood vessels are not working properly. The study will also compare different non-invasive tests, such as blood tests and heart imaging, to see how they relate to the results from the more invasive procedures that assess blood flow.
To be eligible for this trial, participants need to be between 18 and 85 years old and have a confirmed diagnosis of cardiac amyloidosis through a heart biopsy or other biopsy methods. They should also have had specific heart tests done within the last three months. However, patients with serious heart conditions or other health issues that might complicate their participation will not be included. If you join the study, you can expect a thorough evaluation of your heart’s blood flow and overall function, which could help improve understanding and treatment of cardiac amyloidosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject age 18-85 years old
- • Patients with confirmed cardiac amyloidosis by heart biopsy
- • Patients with confirmed amyloidosis by biopsy other than heart and evidence of cardiac involvement in echocardiography
- • Patients who underwent invasive physiologic assessment within 3 months from diagnosis of primary disease
- Exclusion Criteria:
- • Patients with cardiogenic shock
- • Patients with unstable vital sign that precludes coronary angiography
- • Patients with major bleeding in last 3 months
- • Patients with active bleeding
- • Patients with coagulopathy
- • Patients with severe valvular heart disease
- • Patients who refused to provide informed consent
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Joo Myung Lee, MD, MPH, PhD
Principal Investigator
Samsung Medical Center
Eun-Seok Jeon, MD, PhD
Principal Investigator
Samsung Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials